Peritoneal melanosis associated with metastatic melanoma previously treated with targeted and immune checkpoint

Kwang Kiat Sim1, Katie Connell2, Mayank Bhandari3

  • 1Department of General Surgery, Fiona Stanley Hospital, Murdoch, Western Australia, Australia kwang.sim@health.wa.gov.au.

BMJ Case Reports
|January 12, 2021
PubMed

Insights

Peritoneal melanosis, a rare benign condition, presents as dark peritoneal pigmentation. This case suggests immunotherapy-induced tumor regression may cause peritoneal melanosis in metastatic melanoma patients.

Area of Science:

  • Oncology
  • Pathology

Background:

  • Peritoneal melanosis is a rare benign condition characterized by dark peritoneal pigmentation.
  • Its pathophysiology remains unclear, often mimicking metastatic melanoma.

Observation:

  • A case of peritoneal melanosis associated with metastatic melanoma involving the spleen is presented.
  • The patient had prior treatment with targeted therapy and immune checkpoint inhibitors.

Findings:

  • The study explores the potential role of immunotherapy and tumor regression in the pathogenesis of peritoneal melanosis.
  • This is only the third reported case linking peritoneal melanosis with metastatic melanoma.

Implications:

  • Understanding this association may help differentiate benign peritoneal melanosis from metastatic disease.
  • Further research into immunotherapy's effects on peritoneal pigmentation is warranted.

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K